AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in Percent.
The item "Return-On-Total-Capital" stands at 12.22 percent as of 09/30/2025, the highest value at least since 06/30/2022, the period currently displayed.
As of the end of AstraZeneca PLC's third quarter, the item "Return On Total Capital" stands at 12.22 Percent. This represents an increase of 1.25 percentage points compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 3.03 compared to the value the year prior.
The Serie's long term average value is 7.33 percent. It's latest available value, on 09/30/2025, is 4.89 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is +14.13 .
The Serie's change in percentage points from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Return On Total Capital | 905,699,262,464.00 |
![]() | Johnson & Johnson - Return On Total Capital | 486,508,953,600.00 |
![]() | AbbVie Inc - Return On Total Capital | 399,570,305,024.00 |
![]() | Roche Holding AG - Return On Total Capital | 317,433,206,677.55 |
![]() | Novartis AG - Return On Total Capital | 255,096,620,580.91 |